A 4-Period, Placebo-Controlled, Crossover Study to Evaluate the Utility and Feasibility of BOLD fMRI and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (Donepezil and MK3134)
Latest Information Update: 10 May 2022
At a glance
- Drugs MK 3134 (Primary) ; Donepezil
- Indications Dementia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 05 Nov 2014 New trial record